Back to Search
Start Over
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group
- Source :
- Leukemia & Lymphoma. 61:2821-2830
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).AfterAdditive specific inhibition of CML cells by IM/HU was detectedIM/HU combination was more potent in selectively inhibiting CML cells
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Antineoplastic Agents
Chronic myeloid leukaemia
German
03 medical and health sciences
0302 clinical medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
hemic and lymphatic diseases
Internal medicine
medicine
Humans
Hydroxyurea
neoplasms
business.industry
Imatinib
Hematology
medicine.disease
language.human_language
Phase i study
Treatment Outcome
030220 oncology & carcinogenesis
Chronic Disease
Imatinib Mesylate
language
business
030215 immunology
Chronic myelogenous leukemia
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....2d4746fe84a79cad43227efb4e177ca7